RESUMEN
BACKGROUND: The efficacy, tolerability and acceptability of a tea tree oil gel (200 mg/g) and face wash (7 mg/g) were evaluated for the treatment of mild to moderate facial acne. METHODS: In this open-label, uncontrolled phase II pilot study, participants applied tea tree oil products to the face twice daily for 12 weeks and were assessed after 4, 8 and 12 weeks. Efficacy was determined from total numbers of facial acne lesions and the investigator global assessment (IGA) score. Tolerability was evaluated by the frequency of adverse events and the mean tolerability score determined at each visit. Product acceptability was assessed via a questionnaire at the end of the study period. RESULTS: Altogether 18 participants were enrolled, of whom 14 completed the study. Mean total lesion counts were 23.7 at baseline, 17.2 at 4, 15.1 at 8 and 10.7 at 12 weeks. Total lesion counts differed significantly over time by repeated measures anova (P < 0.0001). The mean IGA score was 2.4 at baseline, 2.2 at 4, 2.0 at 8 and 1.9 at 12 weeks, which also differed significantly over time (P = 0.0094). No serious adverse events occurred and minor local tolerability events were limited to peeling, dryness and scaling, all of which resolved without intervention. CONCLUSION: This study shows that the use of the tea tree oil products significantly improved mild to moderate acne and that the products were well tolerated.
Asunto(s)
Acné Vulgar/tratamiento farmacológico , Antiinfecciosos Locales/uso terapéutico , Satisfacción del Paciente , Fitoterapia , Aceite de Árbol de Té/uso terapéutico , Adolescente , Adulto , Antiinfecciosos Locales/efectos adversos , Femenino , Geles , Humanos , Masculino , Proyectos Piloto , Índice de Severidad de la Enfermedad , Encuestas y Cuestionarios , Aceite de Árbol de Té/efectos adversos , Adulto JovenRESUMEN
Calcified marine organisms typically experience increased oxidative stress and changes in mineralization in response to ocean acidification and warming conditions. These effects could hinder the potency of animal weapons, such as the mantis shrimp's raptorial appendage. The mechanical properties of this calcified weapon enable extremely powerful punches to be delivered to prey and aggressors. We examined oxidative stress and exoskeleton structure, mineral content, and mechanical properties of the raptorial appendage and the carapace under long-term ocean acidification and warming conditions. The predatory appendage had significantly higher % Mg under ocean acidification conditions, while oxidative stress levels as well as the % Ca and mechanical properties of the appendage remained unchanged. Thus, mantis shrimp tolerate expanded ranges of pH and temperature without experiencing oxidative stress or functional changes to their weapons. Our findings suggest that these powerful predators will not be hindered under future ocean conditions.
Asunto(s)
Crustáceos/fisiología , Océanos y Mares , Estrés Fisiológico , Movimientos del Agua , Animales , Fenómenos Biomecánicos , Crustáceos/anatomía & histología , Crustáceos/crecimiento & desarrollo , Crustáceos/ultraestructura , Integumento Común/anatomía & histología , Integumento Común/fisiología , Minerales/análisis , Muda , Estrés Oxidativo , Microtomografía por Rayos XRESUMEN
BACKGROUND/OBJECTIVE: The benefit of NB-UVB phototherapy on serum 25-hydroxyvitamin D [25(OH)D] levels in patients with inflammatory skin conditions has been reported in the northern hemisphere. Vitamin D status is known to differ between geographical latitudes. The objective of this study was to investigate the influence of NB-UVB and UVA/UVB phototherapy on the 25(OH)D serum levels in patients with psoriasis and atopic dermatitis in Western Australia. METHODS: A total of 35 patients with psoriasis or atopic dermatitis requiring phototherapy thrice weekly for a minimum of 4 weeks were enrolled. Of these, 20 patients completed the study. Serum vitamin D levels were measured at baseline and at approximately 6 weeks into phototherapy. Data were adjusted for season, patients' age, sex, skin condition and Fitzpatrick skin phototype. RESULTS: There was a statistically significant increase in serum 25(OH)D from pre- to post-NB-UVB and UVA/UVB phototherapy (P < 0.0001), with a mean raw increase of 34.6 (25) nmol/L; or 45.1 (7.5) nmol/L when adjusted for covariates. This was also true for patients receiving NB-UVB phototherapy with a baseline vitamin D of <80 nmol/L (P < 0.05) and >80 nmol/L (P < 0.004). CONCLUSIONS: NB-UVB and UVA/UVB phototherapy significantly increased 25(OH)D serum level in patients with psoriasis and atopic dermatitis in Western Australia. Our study cohort had a higher baseline vitamin D level and a lower percentage increase of serum 25(OH)D post-phototherapy than the increases reported in the literature from cohorts in the northern hemisphere.
Asunto(s)
Dermatitis Atópica/sangre , Psoriasis/sangre , Terapia Ultravioleta , Vitamina D/análogos & derivados , Adulto , Anciano , Anciano de 80 o más Años , Dermatitis Atópica/radioterapia , Humanos , Persona de Mediana Edad , Estudios Prospectivos , Psoriasis/radioterapia , Vitamina D/sangre , Vitamina D/efectos de la radiación , Australia OccidentalRESUMEN
Subcutaneous edema as a presenting feature of dermatomyositis has infrequently been described and is thought to signify a more aggressive disease course. We report a case involving a 38-year-old man who presented with significant subcutaneous edema involving his neck and upper body; he later developed clinical features and biopsy results consistent with dermatomyositis. Only sixteen previous cases of dermatomyositis with subcutaneous edema involving adults have been published in the literature and we aim to review disease progression, prognosis, and optimal treatment of the condition.
Asunto(s)
Dermatomiositis/complicaciones , Edema/etiología , Corticoesteroides/uso terapéutico , Adulto , Autoanticuerpos/sangre , Terapia Combinada , Dermatomiositis/diagnóstico , Dermatomiositis/inmunología , Dermatomiositis/patología , Progresión de la Enfermedad , Quimioterapia Combinada , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , Inmunosupresores/uso terapéutico , Masculino , Metotrexato/uso terapéutico , Debilidad Muscular/etiología , Pronóstico , Respiración Artificial , Insuficiencia Respiratoria/etiología , Insuficiencia Respiratoria/terapia , Tejido Subcutáneo , TraqueostomíaRESUMEN
One of the most visible and potentially disfiguring cutaneous manifestations of tuberous sclerosis complex is the development of multiple facial angiofibromas, present in over 80% of patients. Topical rapamycin has been shown in many reports to be a safe and effective treatment for facial angiofibromas. In February 2012 we reported the results of a pilot study of four patients undertaken at a paediatric tertiary hospital in Australia. Since then, we have continued to refine the optimal formulation and concentration of topical rapamycin and expanded our selection of patients. We present an update on our current cohort of treated patients, discuss the optimal formulation of topical rapamycin and include a literature review on all published cases to date. Although topical rapamycin is not a curative treatment, we have demonstrated that its early institution significantly reduces both the vascularity and palpability of angiofibromas and prevents their progression with age. It is well tolerated and now a cost effective option.
Asunto(s)
Angiofibroma/tratamiento farmacológico , Antibióticos Antineoplásicos/administración & dosificación , Sirolimus/administración & dosificación , Administración Tópica , Adolescente , Angiofibroma/etiología , Niño , Femenino , Estudios de Seguimiento , Humanos , Masculino , Proyectos Piloto , Esclerosis Tuberosa/complicaciones , Adulto JovenRESUMEN
Biological therapy with tumour necrosis factor alpha antibodies continues to offer a life-changing option for a range of autoimmune and inflammatory skin conditions. We present three cases of sarcoidosis, with refractory cutaneous disease successfully treated with infliximab. A review of the literature shows increased numbers of cases of refractory cutaneous sarcoidosis successfully cleared with infliximab therapy.
Asunto(s)
Fármacos Dermatológicos/uso terapéutico , Infliximab/uso terapéutico , Sarcoidosis Pulmonar/tratamiento farmacológico , Enfermedades de la Piel/tratamiento farmacológico , Anciano , Dermatosis Facial/tratamiento farmacológico , Femenino , Humanos , Persona de Mediana Edad , Retratamiento , Dermatosis del Cuero Cabelludo/tratamiento farmacológicoRESUMEN
Epidermolysis bullosa acquisita (EBA) is a chronic, autoimmune condition involving the skin and mucous membranes. Symptomatic mucosal involvement is rare, but can impact on quality of life, due to esophageal strictures and dysphagia. We report a case involving a 60-year-old male presenting with bullous skin lesions on areas of friction on his hands, feet and mouth. Milia were visible on some healed areas. Biopsy showed a subepidermal vesicle. Direct immunofluorescence showed intense linear junctional IgG and C3 at the dermo-epidermal junction. Serological tests also supported the diagnosis of EBA. Screening tests for underlying malignancies were negative. Despite treatment with systemic steroids, the patient developed increasing dysphagia, requiring further investigation with esophagoscopy and a barium swallow. Confirmation of extensive esophageal stricturing prompted adjustment of medications including an increase in systemic steroids and addition of azathioprine. Currently, the patient's disease remains under control, with improvement in all his symptoms and return of anti-basement membrane antibody levels to normal, whilst he remains on azathioprine 150 mg daily and prednisolone 5 mg daily. This case highlights the fact that the treatment of a given patient with EBA depends on severity of disease and co-morbid symptoms. Newer immunoglobulin and biological therapies have shown promise in treatment resistant disease. Considering that long-term immunosuppressants or biologicals will be required, potential side effects of the drugs should be considered. If further deterioration occurs in this patient, cyclosporin A or intravenous immunoglobulin (IV Ig) will be considered. Vigilance for associated co-morbidities, especially malignancies, should always be maintained.
RESUMEN
Malignant melanoma has previously been reported with paraneoplastic syndromes including dermatomyositis. We report a case involving a 34-year-old woman who presented with a persistent skin rash over her neck and upper body, with clinical features suggestive of dermatomyositis. The patient had a history of a right shoulder lesion that was previously removed; a solitary axillary lymph node was detected on additional imaging and biopsy results were consistent with malignant melanoma. The following year, surveillance positron emission tomography scan detected a solitary lung metastasis, leading to a partial lobectomy and confirmation of further spread of the malignant melanoma.
Asunto(s)
Dermatomiositis/diagnóstico por imagen , Dermatomiositis/patología , Neoplasias Pulmonares/secundario , Melanoma/secundario , Síndromes Paraneoplásicos/patología , Neoplasias Cutáneas/patología , Adulto , Alendronato/uso terapéutico , Anticuerpos Antinucleares/sangre , Calcio/uso terapéutico , Fármacos Dermatológicos/uso terapéutico , Dermatomiositis/tratamiento farmacológico , Quimioterapia Combinada , Femenino , Humanos , Neoplasias Pulmonares/diagnóstico por imagen , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/cirugía , Melanoma/diagnóstico por imagen , Melanoma/tratamiento farmacológico , Melanoma/cirugía , Metotrexato/uso terapéutico , Síndromes Paraneoplásicos/diagnóstico por imagen , Síndromes Paraneoplásicos/tratamiento farmacológico , Síndromes Paraneoplásicos/cirugía , Tomografía de Emisión de Positrones , Prednisolona/uso terapéutico , Neoplasias Cutáneas/diagnóstico por imagen , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/cirugía , Resultado del Tratamiento , Vitamina D/uso terapéuticoRESUMEN
Bowel bypass syndrome, also known as bowel-associated dermatitis arthritis syndrome, has been described after a range of intestinal bypass procedures. With the increasing trend in laparoscopic gastric bypass surgery, we report an interesting case of bowel-associated dermatitis arthritis syndrome that developed 12 months following this procedure. A 49-year-old woman presented with ulcerating lesions and pustules on the upper and lower limbs, polyarthralgia, fevers and joint effusions. Before the development of these symptoms she was well, with no significant past medical or family history. A skin biopsy taken from the left shin showed superficial to mid-dermal neutrophilic dermatosis, consistent with bowel-associated dermatitis arthritis syndrome. The patient received corticosteroids, antibiotics and colchicine treatment, with control of disease after continuing with colchicine. This case may illustrate another possible complication following bariatric surgery. The significant time period between the initial surgery and the development of bowel-associated dermatitis arthritis syndrome may mean that more cases of this condition will continue to emerge.